BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival

被引：11

作者：

Barbosa Pagnano, Katia Borgia ^{[1
]}

Bendit, Israel ^{[2
]}

Boquimpani, Carla ^{[3
]}

De Souza, Carmino Antonio ^{[1
]}

Miranda, Eliana C. M. ^{[1
]}

Zalcberg, Ilana ^{[4
]}

Larripa, Irene ^{[5
]}

Nardinelli, Luciana ^{[2
]}

Silveira, Rosana Antunes ^{[1
]}

Fogliatto, Laura ^{[6
]}

Spector, Nelson ^{[7
]}

Funke, Vaneuza ^{[8
]}

Pasquini, Ricardo ^{[8
]}

Hungria, Vania ^{[9
]}

Chiattone, Carlos Sergio ^{[9
]}

Clementino, Nelma ^{[10
]}

Conchon, Monika ^{[11
]}

Beatriz Moiraghi, Elena ^{[12
]}

Lopez, Jose Luis ^{[13
]}

Pavlovsky, Carolina ^{[14
]}

Pavlovsky, Miguel A. ^{[14
]}

Cervera, Eduardo E. ^{[15
]}

Antonio Meillon, Luis ^{[16
]}

Simoes, Belinda ^{[17
]}

Hamerschlak, Nelson ^{[18
]}

Magarinos Bozzano, Alicia Helena ^{[19
]}

Mayta, Ernesto ^{[20
]}

Cortes, Jorge ^{[21
]}

Bengio, Raquel M. ^{[5
]}

机构：

[1] Univ Estadual Campinas, UNICAMP, Hemoctr, BR-13083878 Campinas, SP, Brazil

[2] Univ Sao Paulo, Lab Biol Tumoral, Sao Paulo, SP, Brazil

[3] Hemorio, Rio De Janeiro, RJ, Brazil

[4] Inst Nacl Canc, Rio De Janeiro, RJ, Brazil

[5] Acad Nacl Med Buenos Aires, Inst Invest Hematol, Buenos Aires, DF, Argentina

[6] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil

[7] Univ Fed Rio de Janeiro, Rio De Janeiro, RJ, Brazil

[8] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil

[9] Santa Casa Sao Paulo, Sao Paulo, SP, Brazil

[10] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil

[11] Hosp Santa Marcelina, Sao Paulo, SP, Brazil

[12] Hosp Ramos Mejia, Buenos Aires, DF, Argentina

[13] Banco Municipal Sangre DC, Caracas, Venezuela

[14] FUNDALEU, Buenos Aires, DF, Argentina

[15] INCAN, Mexico City, DF, Mexico

[16] Ctr Med Nacl Siglo XXI, Mexico City, DF, Mexico

[17] Univ Sao Paulo, BR-14049 Ribeirao Preto, SP, Brazil

[18] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil

[19] Hosp Maciel, Montevideo, Uruguay

[20] Inst Oncol Nacl, Panama City, Panama

[21] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CANCER INVESTIGATION | 2015年 / 33卷 / 09期

基金：

巴西圣保罗研究基金会;

关键词：

Chronic myeloid leukemia; BCR-ABL mutations; Imatinib; Resistance; Tyrosine kinase inhibitors; CHRONIC MYELOGENOUS LEUKEMIA; GIMEMA WORKING PARTY; DOMAIN MUTATIONS; EUROPEAN-LEUKEMIANET; IMATINIB RESISTANCE; MANAGEMENT; THERAPY; CML; RECOMMENDATIONS; MESYLATE;

D O I：

10.3109/07357907.2015.1065499

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n=31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p=0.07 and 47% vs. 72%, p=0.03, respectively) and in those with the T315I mutation (p=0.003 and p=0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p=0.01; PFS: 48% vs. 30% p=0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients.

引用

页码：451 / 458

页数：8

共 50 条

[31] Resistance Profiling of BCR-ABL Compound Mutations Linked to Tyrosine Kinase Inhibitor Therapy Failure in Chronic Myeloid Leukemia
Eide, Christopher A.
Zabriskie, Matthew S.
Adrian, Lauren T.
Lange, Thoralf
Deininger, Michael W.
Druker, Brian J.
O'Hare, Thomas
BLOOD, 2011, 118 (21) : 616 - 616
[32] Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia
Leoni, Veronica
Biondi, Andrea
HAEMATOLOGICA, 2015, 100 (03) : 295 - 299
[33] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Druker, BJ
Talpaz, M
Resta, DJ
Peng, B
Buchdunger, E
Ford, JM
Lydon, NB
Kantarjian, H
Capdeville, R
Ohno-Jones, S
Sawyers, CL
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14): : 1031 - 1037
[34] ANALYSIS OF THE REACTIVATION OF HEPATITIS B VIRUS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN TREATMENT WITH INHIBITORS OF THE TYROSINE KINASE BCR-ABL
Sanz Ruperez, A.
Ruiz Gomez, F.
Garcia Gutierrez, V
Herrera Puente, P.
Calbacho Robles, M.
Velazquez Kennedy, K.
Geijo Roman, Martinez C.
Lopez Jimenez, J.
HAEMATOLOGICA, 2017, 102 : 279 - 279
[35] New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Mascarenhas, Cintia C.
Cunha, Anderson F.
Miranda, Eliana C.
Zulli, Roberto
Silveira, Rosana A.
Costa, Fernando F.
Pagnano, Katia B. B.
De Souza, Carmino A.
LEUKEMIA & LYMPHOMA, 2009, 50 (07) : 1148 - 1154
[36] Dynamics of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia (CML) after treatment with one, two or three tyrosine kinase inhibitors (TKI).
Jabbour, Elias
Jones, Dan
Kantarjian, Hagop
O'Brien, Susan
Garcia-Manero, Guillermo
Giles, Francis
Wierda, William
Cortes, Jorge
BLOOD, 2006, 108 (11) : 225A - 225A
[37] Emergence of BCR-ABL Kinase Domain Mutations Associated with Newly Diagnosed Chronic Myeloid Leukemia: A Meta-Analysis of Clinical Trials of Tyrosine Kinase Inhibitors
Ursan, Lulia D.
Jiang, Ruixuan
Pickard, Evan M.
Lee, Todd A.
Ng, Daniel
Pickard, A. Simon
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (02): : 114 - 122
[38] Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
O'Hare, Thomas
Eide, Christopher A.
Deininger, Michael W. N.
BLOOD, 2007, 110 (07) : 2242 - 2249
[39] BCR-ABL independent gene mutations in patients with chronic myeloid leukemia
Schmidt, M.
Rinke, J.
Schaefer, V.
Ziermann, J.
Eigendorff, E.
Hochhaus, A.
Ernst, T.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 210 - 210
[40] Frequency and Clonality of BCR-ABL Compound Mutations in Chronic Myeloid Leukemia
Khorashad, Jamshid
Kelley, Todd W.
Szankasi, Philippe
Adrian, Lauren T.
Eide, Christopher A.
Zabriskie, Matthew S.
Lange, Thoralf
Kraft, Ira L.
Eiring, Anna M.
O'Hare, Thomas
Deininger, Michael W.
BLOOD, 2011, 118 (21) : 1598 - 1599

← 1 2 3 4 5 →